642 related articles for article (PubMed ID: 36166243)
21. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
[TBL] [Abstract][Full Text] [Related]
22. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
Egocheaga MI; Drak Y; Otero V
Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
[TBL] [Abstract][Full Text] [Related]
23. Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.
Rastogi A; Weir MR
J Diabetes Complications; 2023 Aug; 37(8):108515. PubMed ID: 37356235
[TBL] [Abstract][Full Text] [Related]
24. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
26. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
Alfie J; Aparicio LS; Waisman GD
Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
[TBL] [Abstract][Full Text] [Related]
27. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
Ortiz A; Alcázar Arroyo R; Casado Escribano PP; Fernández-Fernández B; Martínez Debén F; Mediavilla JD; Michan-Doña A; Soler MJ; Gorriz JL
Expert Rev Clin Pharmacol; 2023; 16(6):519-531. PubMed ID: 37190957
[TBL] [Abstract][Full Text] [Related]
28. Aldosterone blockade in chronic kidney disease.
Hirsch JS; Drexler Y; Bomback AS
Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
30. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
31. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
32. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
33. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
34. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
35. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Morales E; Huerta A; Gutiérrez E; Gutiérrez Solís E; Segura J; Praga M
Nefrologia; 2009; 29(5):421-9. PubMed ID: 19820754
[TBL] [Abstract][Full Text] [Related]
36. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
37. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
[TBL] [Abstract][Full Text] [Related]
38. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
39. An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
Márquez DF; Ruiz-Hurtado G; Ruilope LM; Segura J
Expert Opin Pharmacother; 2015; 16(15):2283-92. PubMed ID: 26389772
[TBL] [Abstract][Full Text] [Related]
40. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
